Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of auranofin in preparation of medicine for treating castration-resistant prostate cancer

A castration-resistant, prostate cancer technology, applied in the field of biomedicine, can solve the problems of insufficient clinical treatment of tumors and insignificant anti-tumor effects, and achieve the effect of shortening the time, time cost and economic cost of clinical transformation.

Inactive Publication Date: 2020-12-04
JIANGNAN UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But auranofin single use in vivo anti-tumor effect is not obvious, not enough for clinical treatment of tumors, it is extremely necessary to improve the method of its curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of auranofin in preparation of medicine for treating castration-resistant prostate cancer
  • Application of auranofin in preparation of medicine for treating castration-resistant prostate cancer
  • Application of auranofin in preparation of medicine for treating castration-resistant prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The drug sensitivity test of embodiment 1 cell to EPI, Enza

[0038] To detect the drug sensitivity of human prostate cancer cells LNCaP to EPI and Enza.

[0039] 1. Experimental method:

[0040] After the LNCaP cells were plated on a 96-well plate and adhered to the wall overnight, a series of EPI and Enza from high to low concentrations were prepared, and a control group was set up, added to the wells, and three replicate wells were set up for each concentration. After incubation in the cell incubator for 48 hours, CCK8 was added, and after 4 hours, the cell OD value at 450nm wavelength was detected by a full-wavelength multifunctional microplate reader, and the IC50 (half maximal inhibitory concentration) value of EPI and Enza acting on LNCaP cells was calculated.

[0041] 2. The result is as follows figure 1 as shown, figure 1 Among them, graph A is the dose-response curve of LNCaP cells treated with different concentrations of EPI; graph B is the dose-response c...

Embodiment 2

[0043] Example 2 Establishment of prostate cancer LNCaP-drug-tolerant persisters (L-DTP) cell lines resistant to EPI and Enza

[0044] Establish prostate cancer LNCaP-drug-tolerant persisters (L-DTP) cell lines L-DTP-EPI and L-DTP-Enza that are resistant to EPI and Enza. At this time, LNCaP cells can recover drug resistance to EPI and Enza, thereby Mimic CRPC at the cellular level.

[0045] 1. Experimental method:

[0046] In LNCaP cells in a 10cm dish, add EPI (60uM) and Enza (50uM) to treat the cells for 9 days after adhering to the wall overnight, and replace the fresh medium added with drugs every 3 days, and then take 8 of these two drug-resistant cells After the clones were planted in a 96-well plate and adhered to the wall, a series of EPI and Enza from high to low concentrations were prepared, and a control group was set up, added to the wells, and three replicate wells were set for each concentration. After incubation in the cell incubator for 48 hours, CCK8 was add...

Embodiment 3

[0049] Example 3 EPI, Enza respectively combined with Aura drug.

[0050] Further use of CCK8 in L-parent and L-DTP cells were used alone or in combination to illustrate the anti-tumor effect of Aura drugs in L-parent and L-DTP cells in vitro.

[0051] 1. Experimental method

[0052] Normal prostate cancer cells L-parent and drug-resistant cells L-DTP (including L-DTP-EPI and L-DTP-Enza) were planted in 96-well plates, and a series of Aura drugs from high to low were prepared In order to find the highest concentration of Aura without growth inhibition in L-parent cells, set 3 duplicate wells for each concentration, after incubation in the cell culture incubator for 48h, add CCK8, and use the full-wavelength multifunctional enzyme after 4h The standard instrument detects the cell OD value with a wavelength of 450nm, and calculates the survival rate of Aura drug alone in L-parent cells. Then use this concentration to measure the survival rate in L-parent cells with [L-parent-c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of auranofin (Aura) in preparation of a medicine for treating castration-resistant prostate cancer (CRPC), and belongs to the technical field of biological medicines. The invention provides a new strategy used for preparing the CRPC treatment medicine from the Aura and based on combined use of Enza and Aura for the first time, and multi-angle and multi-levelverification research is carried out. The Aura can be used for treating the castration-resistant prostate cancer, significantly improves the castration-resistant prostate cancer inhibition effect of the Enza, realizes new use of the old drug, can greatly shorten the time from drug discovery to clinical transformation, and has important clinical treatment significance.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of auranofin in the preparation of drugs for treating castration-resistant prostate cancer. Background technique [0002] Prostate cancer (PCa) has become the second most common cancer among men and the fifth most common cause of death. In the United States, the incidence rate of males is the first, and the mortality rate is second only to lung cancer; in China, the incidence rate is lower than that in Europe and the United States, but the growth rate is getting faster and faster, posing a serious threat to the survival of men. Androgen deprivation therapy (Androgen deprivation therapy, ADT) is currently the most effective treatment for patients with advanced prostate cancer, effective for more than 85% of patients, but usually progresses to castration inevitably after a median time of 18-24 months Resistant prostate cancer (Castration-resist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7135A61K45/06A61K31/4166A61P35/00
CPCA61K31/7135A61K45/06A61K31/4166A61P35/00A61K2300/00
Inventor 陈永泉王荣朱升龙韦冷云王小英冯宁翰
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com